Alto Neuroscience/$ANRO
1D1W1MYTD1Y5YMAX
Capital at risk
About Alto Neuroscience
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
- Ticker
- $ANRO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 68
- Headquarters
- Mountain View, United States
- Website
- www.altoneuroscience.com
ANRO Metrics
BasicAdvanced
$1.2B
-
-$2.38
1.09
-
Price and volume
Market cap
$1.2B
Beta
1.09
52-week high
$37.48
52-week low
$3.59
Average daily volume
521K
Financial strength
Current ratio
14.852
Quick ratio
14.637
Long term debt to equity
0.083
Total debt to equity
0.106
Interest coverage (TTM)
-39.04%
Profitability
EBITDA (TTM)
-87.584
Management effectiveness
Return on assets (TTM)
-26.79%
Return on equity (TTM)
-49.17%
Valuation
Price to book
4.85
Price to tangible book (TTM)
4.85
Price to free cash flow (TTM)
-15.571
Free cash flow yield (TTM)
-6.42%
Free cash flow per share (TTM)
-1.944
Growth
Earnings per share change (TTM)
-1.06%
What the Analysts think about ANRO
Analyst ratings (Buy, Hold, Sell) for Alto Neuroscience stock.
Analyst projections of the future price of Alto Neuroscience stock.
Bulls say / Bears say
In April 2026, Alto initiated a potentially registrational Phase 2b trial of ALTO-207 in treatment-resistant depression, marking a key progression toward regulatory milestones (Business Wire)
In August 2026, Alto expanded ALTO-207’s development by adding a Phase 3 monotherapy trial, with topline Phase 2b results on track for the second half of 2027, reinforcing sustained pipeline momentum (Business Wire)
In July 2026, Alto completed a $100 million financing, boosting pro forma cash to approximately $338 million and underpinning an expected cash runway through 2030 (Business Wire)
Topline results from the Phase 2 proof-of-concept trial of ALTO-101 in schizophrenia failed to meet its primary cognitive biomarker endpoint in April 2026, underscoring early-stage pipeline risk (Business Wire)
The company’s net loss widened to $27.6 million in Q2 2026 from $17.7 million in Q2 2025, reflecting accelerating cash burn (Business Wire)
Topline data for ALTO-300 and ALTO-100 are not expected until 1H/mid-2027, creating a potentially prolonged catalyst gap in the near term (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 27 Aug 2026.
ANRO Financial Performance
Revenues and expenses
ANRO Earnings Performance
Company profitability
Upcoming events
No upcoming events
ANRO News
AllArticlesVideos
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Business Wire2 weeks ago
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Business Wire3 weeks ago
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Business Wire2 months ago
Funds containing ANRO
AllEURUSDGBP
Fund name | Fund size | $ANRO weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.